EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
GLP-1 PROCUREMENT RESEARCH

Clarity for your next GLP-1 supply decision.

Research and practical tools for US weight-management and telehealth clinics. Compare GLP-1 supply routes, understand total costs and know what to check before choosing a supplier or dispensing partner.

Understand the arrangement.
Know what needs checking.

A pharmacist reviewing a sealed package beside a tablet in a modern pharmacy
Pharmacy operations

First, identify what
the quote actually covers.

Keep formulation, presentation, pack and payer attached to every comparison. Similar descriptions can conceal very different arrangements.

A prescription does not, by itself, establish permission to compound.

Record the preparation, destination and documented basis for review before discussing savings.

Screen a proposed arrangement
01

Identify the preparation

Exact formulation, product status and asserted pathway.

02

Attach the destination

Facility, operating model and destination-state evidence.

03

Name the open questions

Missing evidence stays visible. Assessment incomplete means incomplete.

Why 503A and 503B need different checks +

These are distinct federal frameworks with different conditions. Patient-specific dispensing, facility registration and adding an ingredient do not independently establish permission for a proposed preparation. Read the sourced comparison →

Current source links & dated policy context ↗

Compare arrangements.
Keep responsibilities visible.

Branded access, pharmacy dispensing and proposed compounding require different checks. Start with the same questions.

THE PARTICULARSManufacturer-linked accessPharmacy dispensingProposed compounding
Product status
Manufacturer-linked accessConfirm approved product and presentation
Pharmacy dispensingConfirm exact product dispensed
Proposed compoundingPreparation-specific legal review
Eligibility
Manufacturer-linked accessProgramme and patient terms
Pharmacy dispensingPrescription, payer and state scope
Proposed compoundingApplicable federal and state conditions
Payment & continuity
Manufacturer-linked accessPatient terms; access pathway
Pharmacy dispensingFees, allocation and service levels
Proposed compoundingBasis, provenance and fallback review
Clinic→Dispensing entity→Patient
Open the Access Comparator

Responsibility map only. Programme access is not an assumed wholesale route; patient-specific dispensing is not a separate compounding permission.

Choose the right
level of support.

Find your approach · 2-minute guide

A defined question. A useful working file.

Structure quotes, model costs or organise a supplier evidence file with transparent tools.

Explore the tools

RETAINED RESPONSIBILITY

You confirm inputs and check sources.

Pharmacy professional reviewing a sealed package beside a tablet and research folder
Pharmacy operations
THE WORK YOU TAKE FORWARD

A comparison you can take forward.

  1. 01Confirm the inputs
  2. 02Compare the particulars
  3. 03Export your working file

The quote is one line.
The cost is a schedule.

Compare ongoing economics under matched assumptions. Keep patient, insurer and clinic expenditure separate.

Medicine$400
Dispensing$15
Delivery$20
Clinic handling$10
Per enrolled patient-month$445

Illustrative USD inputs · 100 enrolled months · one monthly pack each · zero extra wastage packs. Costs incurred for all enrolled months.

Calculate your matched costs
ILLUSTRATIVE WORKED EXAMPLE
USD$468.42

per successfully fulfilled
patient-month

An operational proxy, not a clinical outcome.

95 fulfilled months5 unfulfilled months
Each square = one of 100 enrolled patient-months.

Modelled cost: $468.42 per fulfilled month.

Total expenditure ÷ fulfilled patient-months

Something useful
to take to the next meeting.

Preview the structure. Try it with your assumptions. Export a working file your procurement team can act on.

UNGATED PREVIEW

The arrangement, on one sheet.

Every output keeps the assumptions, source limits and unresolved questions alongside the result.

Open this working sheetExplore all ten tools
Dose DiligenceWORKING SHEET
ILLUSTRATIVE EXCERPT

Supply routes

01
Product & presentation

Source / assumption / evidence boundary

02
Operating model & destination

Source / assumption / evidence boundary

03
Eligibility evidence

Source / assumption / evidence boundary

04
Unresolved questions & owner

Next owner: procurement lead · specialist review pending

IDENTIFY → COMPARE → HAND OFF

What changed?
What needs another review?

Practical guidance organised around the decisions on your desk. Read the finding, affected arrangement and evidence boundary together.

4 featured briefings shown. 4 briefings match your filter.

Before the contract,
name the unresolved
questions.

Turn the research into a clear brief: who owns the work, what needs specialist review and what to ask the supplier next.

Prepare your procurement brief

Preview your brief before adding your work email.

ILLUSTRATIVE HAND-OFFDD / 009

Decision pending.
Next steps defined.

Operations ownerClinic procurement lead
Specialist reviewProduct-specific legal basis
Supplier questionWho owns failed-delivery escalation?
Fallback actionConfirm capacity before commitment
Open questions travel with the decision.
01 / IDENTIFYThe exact arrangement
02 / COMPAREThe particulars that matter
03 / HAND OFFThe next responsible action